Explore chapters and articles related to this topic
Antibody-Based Therapies
Published in David E. Thurston, Ilona Pysz, Chemistry and Pharmacology of Anticancer Drugs, 2021
Polatuzumab vedotin (Polivy™) is an ADC designed for the treatment of diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab. It was developed by Genentech/Roche, and was approved by the FDA in 2019.
Antibody–drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin
Published in Expert Review of Clinical Pharmacology, 2020
J. M. Burke, F. Morschhauser, D. Andorsky, C. Lee, J. P. Sharman
In the case of polatuzumab vedotin, the initial demonstration of clinical benefit and FDA approval were for R/R DLBCL. However, polatuzumab vedotin should not be used for all such patients. For example, at the present time a relatively young, fit patient who suffers a first relapse of DLBCL should generally be treated with a salvage chemotherapy regimen that does not contain polatuzumab vedotin, followed by high-dose chemotherapy plus ASCT. Polatuzumab vedotin is reserved for patients with a relapse after ASCT or after one or two lines of chemotherapy in patients who are not candidates for ASCT. An ongoing clinical trial is investigating whether polatuzumab vedotin improves clinical outcomes when given with chemoimmunotherapy as initial therapy for DLBCL. Another area for potential future development of polatuzumab vedotin is in patients with follicular lymphoma, where early studies suggest efficacy with manageable toxicity.
Economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL
Published in Journal of Medical Economics, 2021
Matthias Calamia, Ali McBride, Ivo Abraham
In G029365, the PBR regimen consisted of co-administration of polatuzumab vedotin, bendamustine, and rituximab for up to 6 cycles of 21 days each14. Polatuzumab vedotin was administered intravenously (IV) in a dose of 1.8 mg/kg on day 2 of cycle 1 and day 1 of subsequent cycles. Bendamustine was administered IV in a dose of 90 mg/m2 on days 2 and 3 of cycle 1 and day 1 and 2 of subsequent cycles for a total of two administrations per cycle. Rituximab was administered IV in a dose of 375 mg/m2 on day 1 of each cycle. Premedication included acetaminophen, ondansetron, dexamethasone, and diphenhydramine.
An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma
Published in Expert Review of Hematology, 2020
Moneeza Walji, Sarit Assouline
The US Food and Drug Administration approved the use of polatuzumab vedotin on June 10th, 2019 for R/R DLBCL in combination with bendamustine and rituximab in patients who had received at least 2 prior lines of therapy. The accelerated approval was granted based on the complete response rate seen in the trial in comparison to bendamustine and rituximab. In contrast, the European Medications Agency (EMEA) recently approved the use of polatuzumab BR for R/R DLBCL after one or more prior lines of therapy, citing the trial GO29635 which increased overall survival in this group of patients [55,56].